Pfizer expands immuno-oncology research through Cellectics parnership
- Pfizer is partnering with Cellectics to develop immune-oncology products.
- Cellectics has a proprietary, allogenic platform to develop chimeric antigen receptor T-cell (CAR-T) therapies.
- Pfizer’s payments to Cellectic include an up-front $80 million payment, as well as up to $185 million per product in development, regulatory and commercial milestone payments. Pfizer will also enter into an equity agreement to purchase approximately 10% of Cellectis capital through a stock purchase.
The Cellectis CAR-T platform relies on the allogenic approach, which utilizes engineered T-cells from a single donor that can be used in multiple patients. They can be standardized and shipped on demand or in advance to cancer treatment centers anywhere in the world.
Cellectics brings the platform to this collaborative agreement, with the goal of working on 15 targets that have been chosen by Pfizer. Pfizer will have exclusive rights to develop and commercialize these therapies.